Αρχειοθήκη ιστολογίου

Τετάρτη 30 Μαΐου 2018

Acute Kidney Injury after Liver Transplantation

wk-health-logo.gif

Since the implementation of the MELD score-based allocation system, the number of transplant candidates with impaired renal function has increased. The aims of this review are to present new insights in the definitions and predisposing factors that result in acute kidney injury (AKI), and to propose guidelines for the prevention and treatment of post liver transplantation (LT) AKI. This review is based on both systematic review of relevant literature and expert opinion. Pretransplant AKI is associated with posttransplant morbidity, including prolonged post LT AKI which then predisposes to posttransplant chronic kidney disease (CKD). Prevention of posttransplant AKI is essential in the improvement of long term outcomes. Accurate assessment of baseline kidney function at evaluation is necessary, taking into account that serum creatinine overestimates glomerular filtration rate (GFR). New diagnostic criteria for AKI have been integrated with traditional approaches in patients with cirrhosis to potentially identify AKI earlier and improve outcomes. Delayed introduction or complete elimination of calcineurin inhibitors during the first weeks post LT in patients with early posttransplant AKI may improve GFR in high risk patients but with higher rates of rejection and more adverse events. Biomarkers may in the future provide diagnostic information such as etiology of AKI, and prognostic information on renal recovery post-LT, and potentially impact the decision for simultaneous liver-kidney transplantation. Overall, more attention should be paid to pretransplant and early posttransplant AKI to reduce the burden of late CKD. Corresponding Author Mitra K. Nadim, MD, FASN, Professor of Clinical Medicine, Division of Nephrology & Hypertension, Department of Medicine, University of Southern California, 1520 San Pablo St., Suite 4300, Los Angeles, CA 90033 AUTHORSHIP All authors participated in writing of the article DISCLOSURE The authors declare no conflicts of interest Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2kBH1N6

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου